Morgan Stanley Graybug Vision, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.46 - $1.05 $643 - $1,468	1,399 Added 11.65%	13,410 $6,000
Q3 2022 Nov 14, 2022	BUY	$0.93 - $1.18 $2,790 - $3,541	3,001 Added 33.31%	12,011 $11,000
Q2 2022 Oct 27, 2022	SELL	$0.76 - $1.25 $115,697 - $190,292	-152,234 Reduced 94.41%	9,010 $10,000
Q2 2022 Aug 15, 2022	SELL	$0.76 - $1.25 $115,697 - $190,292	-152,234 Reduced 94.41%	9,010 $10,000
Q1 2022 Oct 27, 2022	BUY	$1.13 - $1.93 $172,024 - $293,811	152,234 Added 1689.61%	161,244 $198,000
Q1 2022 May 13, 2022	SELL	$1.13 - $1.93 $264,521 - $451,793	-234,090 Reduced 59.21%	161,244 $198,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $3.6 $155,531 - $321,789	89,386 Added 29.22%	395,334 $724,000
Q3 2021 Nov 15, 2021	BUY	$3.18 - $5.17 $972,914 - $1.58 Million	305,948 New	305,948 $1.02 Million

Ticker GRAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,517,700
Market Cap $63.5M
Description
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the t...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.